Is VYNE Therapeutics Inc. (VYNE) a Buy, Sell, or Hold?
NASDAQ : VYNE
VYNE Therapeutics Inc.
$0.761 USD
-$0.01 (-0.85%)
- Volume
- 984.55K
- Average Volume
- 534.06K
- Market Capitalization
- $12.68M
- P/E Ratio
- -1.57
- Dividend Yield
- 0.00%
- Price Target
- $5.75
- Year High
- $1.60
- Year Low
- $0.28
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $20.86
Company Overview
NASDAQ
David T. Domzalski
Biotechnology
Healthcare
VYNE
10
US
USD
Liquidity Metrics
0.00
20.86
20.86
19.93
0.00
Sales & Valuation
$570K
27.93
1.32
-0.49
-0.60
Profitability
-$0.62
-$26.48M
-4726.21%
-4782.82%
-69.57%
-82.93%
P/E Metrics
-1.57
-0.02
-0.02
Analyst Price Target & Rating
$5.75
$5.75
$5.75
2/5
2 Analysts
-86.77%
Poll Results
About VYNE Therapeutics Inc. (NASDAQ:VYNE) Stock
VYNE Therapeutics Inc. is a pharmaceutical enterprise dedicated to discovering and advancing therapies for immune-mediated inflammatory conditions. Its development portfolio features FCD105, a topical foam formulation that has successfully finished Phase III clinical studies for the management of moderate-to-severe acne vulgaris. Another candidate in its pipeline is FMX114, a combination treatment incorporating tofacitinib, which is currently in early-stage clinical assessment, referred to as a Phase IIa preclinical trial, for addressing mild-to-moderate atopic dermatitis. Additionally, the company is progressing VYN201, a bromodomain and extra-terminal (BET) inhibitor designed to target a range of immuno-inflammatory disorders, notably those affecting the skin. A further asset is VYN202, ... which comprises BET inhibitor compounds engineered for selective action on bromodomain 2. Established in 2003, the firm was formerly recognized as Menlo Therapeutics Inc. before officially changing its corporate identity to VYNE Therapeutics Inc. in September 2020. The company's principal operations are based in Bridgewater, New Jersey.
2026-07-10 08:00:00
Aggregate cash dividend of an estimated $16.5 million, or an estimated $0.38 per share Aggregate cash dividend of an estimated $16.5 million, or an estimated $0.38 per share
Frequently Asked Questions
-
What is the current VYNE Therapeutics Inc. (VYNE) stock price?
-
VYNE Therapeutics Inc.(NASDAQ:VYNE) stock price is $0.761 in the last trading session. During the trading session, VYNE stock reached the peak price of $1.595 while $0.281 was the lowest point it dropped to. The percentage change in VYNE stock occurred in the recent session was --0.85% while the dollar amount for the price change in VYNE stock was -$0.01.
-
VYNE's industry and sector of operation?
-
The NASDAQ listed VYNE is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of VYNE?
-
David T. Domzalski | Chief Executive Officer, President & Director
Mutya Harsch | General Counsel, Chief Legal Officer & Company Secretary
Tyler Zeronda | Chief Financial Officer & Treasurer
Darrell S. Rigel | Consultant
Iain A. Stuart | Chief Scientific Officer -
How many employees does VYNE have?
-
Number of VYNE employees currently stands at 10. VYNE operates from P.O. Box 125, Stewartsville, NJ 08807, US.
-
Link for VYNE official website?
-
Official Website of VYNE is: https://www.vynetherapeutics.com
-
How do I contact VYNE?
-
VYNE could be contacted at phone #800 775 7936 and can also be accessed through its website. VYNE operates from P.O. Box 125, Stewartsville, NJ 08807, US.
-
How many shares of VYNE are traded daily?
-
The average number of VYNE shares traded daily for last 3 months was 534.06K.
-
What is the market cap of VYNE currently?
-
The market value of VYNE currently stands at $12.68M with its latest stock price at $0.761